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Abstract
The epithelial to mesenchymal transition (EMT) is a developmental program in which epithelial cells down-regulate their
cell-cell junctions, acquire spindle cell morphology and exhibit cellular motility. In human breast cancer, invasion into
surrounding tissue is the first step in metastatic progression. Here, we devised an in vitro model using selected cell lines,
which recapitulates many features of EMT as observed in human breast cancer. By comparing the gene expression profiles
of claudin-low breast cancers with the experimental model, we identified a 9-gene signature characteristic of EMT. This
signature was found to distinguish a series of breast cancer cell lines that have demonstrable, classical EMT hallmarks,
including loss of E-cadherin protein and acquisition of N-cadherin and vimentin expression. We subsequently developed a
three-dimensional model to recapitulate the process of EMT with these cell lines. The cells maintain epithelial morphology
when encapsulated in a reconstituted basement membrane, but undergo spontaneous EMT and invade into surrounding
collagen in the absence of exogenous cues. Collectively, this model of EMT in vitro reveals the behaviour of breast cancer
cells beyond the basement membrane breach and recapitulates the in vivo context for further investigation into EMT and
drugs that may interfere with it.
Citation: Katz E, Dubois-Marshall S, Sims AH, Gautier P, Caldwell H, et al. (2011) An In Vitro Model That Recapitulates the Epithelial to Mesenchymal Transition
(EMT) in Human Breast Cancer. PLoS ONE 6(2): e17083. doi:10.1371/journal.pone.0017083
Editor: Syed Aziz, Health Canada, Canada
Received November 9, 2010; Accepted January 14, 2011; Published February 15, 2011
Copyright:  2011 Katz et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: Clinical materials were obtained through the auspices of the Edinburgh Experimental Cancer Medicine Centre. This work was supported by
Breakthrough Breast Cancer and the Scottish Funding Council. The funders had no role in study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: elad.katz@ed.ac.uk
Introduction
Breast cancer related deaths are primarily due to metastatic
progression [1]. Understanding the mechanisms that underlie this
multistep process is essential to improving clinical outcome. The
transformation of normal breast epithelial cells to metastatic
cancer is the result of multiple epigenetic and genetic changes,
leading to deregulated interactions with the microenvironment [2].
During this process, inhibition of proliferation, cell survival,
migration and differentiation is lost leading to the acquisition of an
invasive phenotype. The ability to breach the basement membrane
(BM) is a critical event in cancer progression and a prerequisite for
metastasis. Having breached the BM, cells may then enter the
lymphatic system, spread and attempt to establish themselves as
distant tumor foci [3].
The trans-differentiation of cells from an epithelial to a
mesenchymal phenotype is an essential part of normal embryo-
genesis and development [4]. Increasing evidence also supports a
role for epithelial to mesenchymal transition (EMT) in the
progression of many cancer types including breast, with critical
roles in invasion and metastatic dissemination [5,6]. EMT involves
loss of cell-cell junctions and re-organization of the actin
cytoskeleton, resulting in loss of apical-basal polarity and
acquisition of a spindle-like mesenchymal morphology [7]. At
the same time, there is also decreased expression of epithelial-
specific proteins, including E-cadherin, which may account at least
in part for the altered properties of migrating tumor cells [8,9]. An
important event in EMT is switching in expression from E-
cadherin to N-cadherin [10]. In most cases this is associated with
transcriptional repression of E-cadherin [9]. Several specific
repressor factors have been identified including Snail, Slug,
Zeb1, Zeb2 and Twist [11], all of which are zinc finger containing
proteins that can bind with so called E-boxes within the CDH1
gene promoter. N-cadherin is believed to promote cellular
invasion by binding to and enhancing signalling by growth factors
and is over-expressed in many invasive and metastatic human
breast cancer cell lines and tumors [10,12,13].
Comparative analysis of mouse mammary carcinoma models
and human breast tumors identified a novel human molecular
subtype, termed ‘claudin-low’ cancers. These cancers are char-
acterised by low to absent expression of genes involved in tight
junctions and cell-cell adhesions, including claudins, occludins and
E-cadherin [14,15]. In addition, these moderate-high grade
invasive ductal carcinomas are morphologically distinct from
lobular carcinomas despite their low expression of E-cadherin
[14]. Similarities between claudin-low tumors and EMT in vitro
have been documented, however these features have not
previously been compared and analysed directly. Furthermore,
while the contribution of the extra-cellular matrix to the
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promotion of tumor progression is now appreciated [2], most
current in vitro models do not take into account the contribution of
stromal collagen into which cells undergoing EMT invade. The
predisposition of tumours to undergo EMT can be enhanced by
genetic alterations. For example, C35 is a 12KDa membrane-
anchored protein found on the HER2 amplicon that is over-
expressed in around 11% of breast cancers [16]. Cellular
transformation associated with acquisition of an EMT phenotype
can be induced in mammary epithelial cells transfected with a C35
expression construct resulting in increased invasion into stromal
collagen, down regulation of E-cadherin and up regulation of the
transcription repressor Twist [17]. This implies that collagen-
invading C35-expressing cells can be used to model aspects of
EMT in cancer cells.
Testing new treatments that may prevent EMT or tumor spread is
challenging: conventional clinical trials may have difficulty in
addressing the issues because of the ethical problems of leaving
tumor in situ, or the limitation of a study to only very late stage disease.
Robust models that can identify possible predictive biomarkers are
essential. In this report, we describe a unique invasion assay, in which
cell lines with known molecular pathology undergo spontaneous
EMT when invading away from the basement membrane into
collagen. We propose that this in vitro model of defined breast cancer
cell lines can provide an improved representation of invasive breast
cancer in vivo, compared to existing EMT models.
Materials and Methods
Gene expression analysis, RNA extraction and qRT-PCR
Microarray data was analysed using packages within Biocon-
ductor [18] (http://www.bioconductor.org) that implement R
statistical programming. Gene expression data was normalised
using quantile normalisation within the BeadArray package [19]
and differential gene expression assessed using Significance
Analysis of Microarrays (SAM) [20] within the siggenes package.
The dataset from Hershkowitz and colleagues [14] was down-
loaded from the UNC Microarray Database (https://genome.unc.
edu/). RNA from the collagen invasion assays was labelled using a
Illumina TotalPrep RNA amplification kit (Ambion) according to
manufacturer’s instructions. Triplicate samples from invasion
assays (1500 ng cDNA per assay) were hybridised to Illumina
BeadChips and whole genome gene expression analysis performed
using the Illumina HumanRef-8 v3 Expression BeadChip and
BeadArray Reader.
RNA from cell lines cultured on plastic was converted to cDNA
prior to PCR using a QuantiTect Reverse Transcription kit
(Qiagen). Gene expression patterns for invasion assays (biological
triplicates) and cell lines cultured on plastic (technical triplicates)
were examined using the QuantiTect SYBR Green PCR kit
(Qiagen) and a Corbett RotoGene 3000. Primers for CDH1 were:
forward 59-CGGAGAAGAGGACCAGGACT-39, reverse 59-
GGTCAGTATCAGCCGCTTTC-39; for CLDN7: forward 59-
AAAATGTACGACTCGGTGCTC-39, reverse 59-AGACCTGC-
CACGATGAAAAT; for TBP: forward 59-GGGGAGCTGTGA-
TGTGAAGT-39, reverse 59-CCAGGAAATAACTCTGGCTCA-
39; for ACTB: forward 59-CCTTCCTGGGCATGGAGTCCT-39,
reverse 59-GGAGCAATGATCTTGATCTT-39. QuantiTect
Primer Assays (Qiagen) were used for KRT8, CRB3, MARVELD3,
IRF6, MAL2, TACSTD1 and SPINT2. PCR program was identical
for all genes: 95uC, 15 min; (94uC, 15 s; 56uC, 30 s; 72uC, 30 s)650
cycles; 72uC, 5 min. Standard reference human cDNA was from
Clontech, random primed. ,50 ng RNA equiv/mL was used for
quantification of mRNA expression. Final normalisation was
performed against the geometrical mean of ACTB and TBP levels.
Gene promoter analysis
Using the presumptive promoter region for the 9 genes (a 2 kb
region upstream of the presumptive transcription start site using
Ensembl 52, Jan2009, based on NCBI 36 assembly), we looked for
over-represented 6- and 7-mers oligos using oligo-analysis [21] from
the RSAT-tools package (http://rsat.scmbb.ulb.ac.be/rsat/) [22].
The program counts all oligonucleotide occurrences within the
sequence set, and estimates their statistical significance. A
calibration is done using the entire genome promoter regions as a
background model (Ensembl 52, Jan2009, based on NCBI 36
assembly). For the best 7-mers candidates, we compared the
obtained oligo sequences to the entire collection of consensus
binding sites available in Transfac professional [23] (release 2010.1)
using the compare-pattern script (RSAT-tools) and listed the
associated binding factor name.
E-value for best hit 7-mer CAGGTGC/GCACCTG
(2.661028) represents the expected number of patterns which
would be returned at random for a given probability. The weights
in Table 1 reflect the number of matching positions, with a lower
weight for matches between partially specified nucleotides (the
weight for a perfect match to a 7-mer is 7). Both E-value and
weights are calculated by RSAT-tools.
Cell lines
MCF10A, Hs578T, HBL100, BT549, MDA-MB157, MDA-
MB231 and MDA-MB436 cell lines were obtained from American
Type Culture Collection. SUM159PT and SUM1315MO2 cells
were a kind gift from Akira Orimo (University of Manchester).
The cells were cultured as previous described [24] at 37 deg C, 5%
CO2: MCF10A in DMEM/F12 media (Invitrogen) with 5% horse
serum (Invitrogen), 20 ng/ml EGF, 100 ng/ml cholera toxin,
0.01 mg/ml insulin and 500 ng/ml hydrocortisone (all from
Sigma); MDA-MB157, MDA-MB231, HBL100 and HS578T in
DMEM, 10% bovine serum (both from Invitrogen); SUM159PT
in Ham’s F12 (Invitrogen), 5% bovine serum, insulin, hydrocor-
tisone; MDA-MB436 in L15 (Invitrogen), 10% bovine serum;
BT549: RPMI-1640, 10% bovine serum; SUM1315MO2 in
Ham’s F12, 5% bovine serum, insulin, EGF.
Primary cell isolation for tissue culture
Fresh normal breast tissue and breast tumor materials were
incubated for 1 hour at room temperature in tissue mix consisting of
DMEM/F12, 1% fungizone, 1000 U/ml penicillin, 1000 mg/ml
streptomycin, 10 mg/ml insulin and 10% bovine serum (all from
Invitrogen). Tissue cores were then finely chopped (,1 ml pieces)
and put in a tissue mix/Collagenase I solution (Invitrogen; made up
with 200 mL of 200 U/ml Collagenase I to 20 ml tissue mix) for
digestion (2 hours at 37 deg C, 200 rpm). The digested tissue was
then spun for 4 mins at 60 g. The resulting pellet was plated with
fibroblast media (DMEM supplemented with 10% bovine serum,
50 U/ml penicillin and 50 mg/ml streptomycin) and the superna-
tant spun for a further 4 mins at 600 g, 4 times. The resulting
second pellet (mammary epithelial cells) was plated with HMEC
media (CnT-22 (Cellntec) supplemented with 5% FCS).
Ethics Statement
The use of primary breast cells was approved by the Lothian
Research Ethics Committee (08/S1101/41). Materials were
obtained with written informed consent from all participants
involved in this study.
Rat tails obtained from animals at the University of Edinburgh
animal facilities scarified for other scientific purposes and did not
require ethical approval.
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SDS-PAGE
Protein lysates (50 mg/well, as determined by MicroBCA
protein assay) were resolved by SDS-PAGE after being denatured
for 1 hour at 60 deg C. The resolving gel (7.5% w/v acrylamide,
0.37 M TRIS pH 8.85, 0.1% SDS, 0.02% AMPS, 0.25%
TEMED; all from Sigma) was set between glass plates using a
Bio-Rad kit. Once the resolving gel had set, a stacking gel (3.6%
w/v acrylamide, 0.12 M TRIS pH 6.8, 0.1% SDS, 0.03% AMPS,
0.33% TEMED) was layered and a comb used to create wells for
sample loading. The loaded samples were electro-separated under
constant current (100–200 mA) using electrophoresis buffer
(25 mM Trizma Base, 0.19 M Glycine, 10% SDS). Electro-
transfer onto immobilon transfer membrane (Millipore) was
performed using transfer buffer (25 mM Trizma Base, 0.19 M
Glycine) using a Bio-Rad kit, under constant electrical potential
(,30 mV for at least 2 hours).
Western Blotting
Nonspecific binding was blocked with Li-Cor Odyssey Blocking
Buffer (Li-Cor), diluted 50:50 in PBS, for 1 hour at room
temperature. Primary antibodies were diluted in Li-Cor Odyssey
Blocking Buffer, diluted 50:50 in 0.1% PBS-Tween20, and
incubated with the blot overnight at 4 deg C. Blots were washed
3 times for 5 mins with PBS-T before incubation with appropriate
fluorescent secondary antibodies (Li-Cor), diluted 1:10,000 in Li-
Cor Odyssey Blocking Buffer, diluted 50:50 in 0.1% PBS-
Tween20, for 45 mins at room temperature. Exposure to light
was avoided. Subsequently, membranes were washed, dried and
scanned on the Li-Cor Odyssey scanner. All washes/incubations
were carried out under constant agitation. Primary antibodies used
as follows: E-cadherin, BD, 610181, Mouse, 1:2500; Claudin7,
Abcam, Ab75347, Rabbit, 1:1000; N-cadherin, BD, 610921,
Mouse, 1:3000; Vimentin, Sigma, V 6630, Mouse, 1:1000; Zeb2,
BD, 611256, Mouse, 1:250; Slug, LifeSpan Bio, LS-C30318,
Rabbit, 1:4000; Snail, Abcam, ab17732, Rabbit, 1:4000; Tubulin,
Abcam, Ab7291, Mouse, 1:6000.
Rat tail collagen I preparation
Fresh rat tails were collected and frozen. Prior to harvesting
these were placed in 70% ethanol. Tendons were stripped from
the tails and returned to 70% ethanol to sterilise. The collected
tendons were weighed and transferred to the appropriate volume
of pre-cooled acetic acid (1 g tendon to 250 ml 0.5 M acetic acid)
and gently stirred for 48 hours at 4 deg C. The tendon/acetic acid
mix was then centrifuged at 10,000 g for 30 mins and the pellet
discarded. An equal volume of 10% (w/v) NaCl was added to the
supernatant and the mix allowed to stand overnight at 4 deg C.
The collagen-rich, insoluble ‘bottom layer’ was taken and collected
by further centrifugation (10,000 g for 30 mins). The collagen-rich
material was resuspended in 0.25 M acetic acid at 4 deg C and
dialysed against 1:1000 acetic acid at 4 deg C for 3 days, changing
the dialysis buffer twice daily. The collagen solution was then
sterilised by centrifugation (20,000 g for 2 hours) and stored at 4
deg C. Collagen was diluted as required by the addition of sterile
1:1000 acetic acid to a stock concentration of 1.2 mg/ml.
Establishment of 3D invasion assays
200 mL cell-collagen plugs and 75 mL cell-Matrigel plugs were
made in a u-shaped 96 well plate, with the aim of achieving
comparable size after a 24 hr incubation (day -1). A cell
concentration of 16106 was used for all plugs. Rat tail collagen
I, for both plugs and subsequent embedding, was prepared as per
the ‘on top’ assays. Growth factor reduced Matrigel was obtained
from BD and used at a 5 mg/ml. Matrigel matrix is a soluble
basement membrane extract of the Engelbreth-Holm-Swarm
tumor that gels at room temperature to form a reconstituted
basement membrane. The major components are laminin,
collagen IV, entactin and heparin sulphate membrane. After the
24 hr incubation, cell plugs were carefully removed from their 96
well plate and embedded in 1 ml of collagen in a 24 well plate
(taken as day 0), with or without fibroblasts (used at 10,000/ml).
These cultures were incubated for a further hour and then
carefully freed from the edges of the well (to allow contraction of
the collagen) and supplemented with 0.5 ml of cell-specific media.
The cultures were then left to invade. Media was changed weekly.
Gels were fixed at either 1 or 2 weeks in 10% phosphate buffered
formalin and wax embedded.
Immunofluorescence
Immunofluorescence was preformed as described previously
[17]. Briefly, antigen retrieval for all epitopes was carried out using
heat treatment under pressure in a microwave oven for 5 min in
Table 1. Common transcription factor binding sites in the 9-gene signature.
Best hit Weight Matrix consensus Transfac ID Factor name
GCACCTG 6.5 ASCACCTGTTNNCA M00044 Snail*
CAGGTGC 6.5 RACAGGTGYA M00060 Snail*
GCACCTG 6.5 VNRCACCTGKNC M00414 AREB6/ZEB1*
CAGGTGC 6.21 CNNCAGGTGB M00277 LMO2 complex*
CAGGTGC 6 RRCAGGTGNCV M00693 E12/ELSPBP1*
CAGGTGC 6 CNGNRNCAGGTGNNGNA M00929 MyoD*
GCACCTG 5.5 YNYACCTGWVT M00412 AREB6/ZEB1*
GCACCTG 4 RRTGNMCYTNNTGAMCCNYNT M00966 VDR, CAR, PXR
GCACCTG 3.5 GCTGGNTNGNNCYNG M00947 CP2/LBP-1c/LSF
GCACCTG 3.5 RGNACNNKNTGTTCT M00957 PR/Progesterone receptor
GCACCTG 3.5 TGGCASNNNGCCAA M01196 CTF1
A list of binding sites matching to best 7-mer found in promoters of the common EMT gene signature. Three muscle initiator sequences with no further information
were excluded.
*E-box binding transcription factors. E12 is part of the LMO2 complex.
doi:10.1371/journal.pone.0017083.t001
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citrate buffer (82 ml 0.01 M sodium citrate: 18 ml 0.01 M citric
acid) pH 6.0. Slides were incubated with primary antibodies for
1 hr at room temperature. Primary antibodies were as follows: E-
cadherin, BD, 610181, Mouse, 1:1500; N-cadherin, BD, 610921,
Mouse, 1:300; Zeb2, BD, 611256, Mouse, 1:50; Slug, LifeSpan Bio,
LS-C30318, Rabbit, 1:1000; Snail, Abcam, ab17732, Rabbit,
1:700. For Snail staining, mouse anti-pancytokeratin (Invitrogen,
1:25) was added to visualise epithelial cells. Mouse primary
antibodies were incubated overnight with rabbit anti-pancytoker-
atin (Dako, 1:150). The epithelial compartment was then visualised
with Cy3 (Invitrogen, anti-rabbit; anti-mouse, both used at 1:25).
DAPI (49,6-diamidino-2-phenylindole) counterstain (Invitrogen)
was used to identify nuclei and Cy-5-tyramide (HistoRx, 1:50)
was used to detect protein ‘targets’. Monochromatic images of each
TMA core were captured at 206objective using an Olympus AX-
51 epifluorescence microscope, and high-resolution digital images
were analyzed by the AQUAnalysis software [17].
Results
Identification of a common EMT signature in the breast
In order to establish an in vitro EMT signature, we identified a
set of 57 genes that strongly correlated with C35-induced EMT in
vitro using significance analysis of microarrays (SAM, [20]). These
‘C35 genes’ were subsequently found to be sufficient to cluster
claudin-low tumors together in a breast cancer dataset [14] (Figs. 1
and S1). In addition, a 34 gene ‘claudin-low’ signature identified in
murine mammary carcinoma and human breast tumors [14], was
significantly down-regulated in collagen-invading C35-expressing
cells in comparison to parental cells (range p= 0.048 to
p= 161028; Figs. 1 and S1). Nine genes were common between
the ‘C35 genes’ and ‘claudin-low genes’ signatures (Fig. 1): CDH1,
CLDN7, CRB3, KRT8, TACSTD1, IRF6, SPINT2, MAL2 and
MARVELD3. Five of these, CDH1 (E-cadherin), CLDN7 (Claudin-
7), TACSTD1 (EpCAM), IRF6 and KRT8 (Keratin-8) have been
previously implicated by their low expression in claudin-low
cancers and/or in EMT in vitro [25,26,27]. SPINT2 (Hepatocyte
growth factor activation inhibitor-2, HAI-2) is capable of
regulating a HGF-induced invasion of human breast cancer cells
[28]. Two novel genes found to be down-regulated: the apical
sorting protein MAL2 [29] and its tight-junction-associated
homologue MARVELD3 [30].
We determined whether the nine EMT genes share common
regulatory elements in their promoters and identified a shared 7-
mer: CAGGTGC/GCACCTG. This binding motif is targeted by
E-box transcription repressors, including Snail and ZEB families
(Table 1) raising the possibility that these transcription factors
repress all nine genes in the EMT pathway both in vitro and in vivo.
Figure 1. Comparison of genes correlating with C35 expression and those identifying the claudin-low phenotype identifies a 9-
gene EMT signature. The 100 illumina probes most significantly differentially expressed between collagen-invading C35 and parental cells were
represented by 57 genes that were able to cluster together the 13 claudin-low tumors identified by Herschkowitz and colleagues (left panels). A set of
34 claudin-low genes from the Herschkowitz were all significantly down-regulated in C35-expressing cells compared to parental cells (right panels). A
signature of nine EMT-related genes is shared between the C35 and claudin-low gene lists (full lists in Fig. S1).
doi:10.1371/journal.pone.0017083.g001
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Identification of cell lines with ‘claudin-low’ features
The 9-gene signature was identified in nine breast cancer cell
lines from a previously published gene expression dataset [24] that
all expressed low levels of the EMT genes: cell lines BT549,
Hs578T, HBL100, MDA-MB157, MDA-MB231, MDA-MB435,
MDA-MB436, SUM1315MO2 and SUM159PT respectively. We
excluded the MDA-MB435 line from this cohort of cell lines due
to doubts as to its tissue of origin [31]. The remaining eight cell
lines show clear mesenchymal morphology when cultured on
plastic (Fig. S2). We confirmed down-regulation of eight of the
nine EMT genes by quantitative RT-PCR (Fig. 2) using normal
human mammary epithelial cells (HMECs) as a positive control.
We also validated low expression of these genes in the C35 model
([17] and data not shown).
Western blotting was used to investigate the expression patterns
of EMT-related proteins, including transcription repressors. All
lines exhibit low levels of E-cadherin and Claudin-7 in comparison
to normal mammary epithelial cells (Fig. 3), whereas ZEB2 (SIP-
1), an E-box transcription factor that can induce EMT, is
expressed in all the cell lines with claudin-low features. Most of
the cell lines also have detectable expression of Snail, whereas Slug
is absent in only one (MDA-MB231). Lastly, all of the cell lines
express the mesenchymal marker vimentin and seven of the cell
lines have detectable expression of N-cadherin.
A 3D invasion assay that mimics invasion into stromal
collagen
A critical event in cancer progression is the acquisition of an
invasive phenotype, and in particular the ability to breach the
basement membrane (BM) into the stromal collagen. We
developed a 3D model that attempts to mimic this process.
Histologically normal breast epithelial cells are first embedded in a
laminin-rich, BM-like Matrigel to generate a cell ‘plug’ which was
subsequently embedded in collagen to mimic the surrounding
extracellular matrix (Fig. 4a). This model potentially generates a
three-stage assay that allows investigation of cells: i) contained by
BM; ii) as they invade across BM; iii) as they invade more distally
into surrounding collagen. In addition, the movement of cells in a
horizontal plane can easily be followed by light microscopy, in
Figure 2. The 9-gene C35/claudin-low signature is down-regulated in a subset of human breast cell lines. Eight cell lines exhibit low
expression of CDH1, CLDN7, CRB3, KRT8, TACSTD1, IRF6, SPINT2 and MAL2 when cultured on plastic. MARVELD3 could not be assessed due to
particularly low levels of expression. Technical triplicate mRNA expression data is shown for each line. HMEC cDNA is shown for comparison.
doi:10.1371/journal.pone.0017083.g002
Figure 3. Claudin-low-like cell lines express key markers of
EMT. Western blots demonstrate the expression of EMT-related
markers at the protein level. HMEC lysates are shown for comparison.
doi:10.1371/journal.pone.0017083.g003
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contrast to the movement of cells in a vertical plane that occurs
with the collagen-based ‘on top’ assay [17].
Three different cell lines with low expression of the 9-gene EMT
signature (HBL100, HS578T and SUM 159PT) demonstrated
clear and reproducible invasion in this novel assay. Importantly,
all three cell lines adopt a round morphology when embedded in
Matrigel (day 0), versus the predominantly elongated morphology
that is seen in collagen (Fig. S3). By day 7, the HBL100 and
HS578T cells have reverted to an elongated morphology,
indistinguishable from that seen in collagen, and are invading
across BM and into surrounding collagen. In contrast, many
SUM159PT cells retain a round morphology, accompanied by
delayed invasion (Fig. 4b). By day 14, SUM159PT cells appear to
have overcome this inhibition and many elongated cells are now
seen leaving the Matrigel plug. Those cells that remain in the
Matrigel plug still retain a more round morphology (Fig. 5a).
MCF10A cells (a non-transformed line) were also tested in this
assay and do exhibit an invasion phenotype. As expected,
MCF10A cells appear to form polarised, growth arrested
structures [32]. These observations suggest that this model may
allow the investigation of cells as they invade across the BM.
Importantly, SUM159PT cells are the most affected by Matrigel in
terms of morphology and invasive capacity, and were therefore
selected for further investigation.
SUM159PT cells, which are an excellent metastasis model in vivo
[33,34], were selected for further EMT analysis with MCF10A cells
serving as a control, as they show uniform, membranous expression
of E-cadherin and no expression of N-cadherin. In contrast,
SUM159PT cells show no membrane-specific E-cadherin expres-
sion but do show membranous N-cadherin expression throughout
the core of the plug (Fig. 5b). In the elongated invading cells at the
periphery N-cadherin expression appears to be down-regulated.
Stromal fibroblasts have been shown to play critical roles in some
models of invasion, remodelling the ECM and generating tracks
along which epithelial cells can follow [35]. The role of normal and
cancer-associated fibroblasts (CAFs) was therefore also investigated.
No difference in invasion was evident with both normal fibroblasts
and CAFs. This lack of effect on invasion was seen when epithelial
cells were embedded in both collagen and Matrigel (Fig. S4).
Discussion
This study identifies 9 key genes shared by breast cells
undergoing EMT in vitro and EMT enriched claudin-low tumors.
Figure 4. A novel invasion assay mimics EMT. (a) Schematic illustration of the ‘plug’ invasion assays. A collagen- or Matrigel-based epithelial
plug is embedded in additional collagen, with or without fibroblasts. Epithelial cells then invade in a star-burst manner into surrounding collagen. (b)
Morphological changes suggestive of spontaneous transitions between MET and EMT states are observed by light microscopy. Cell-collagen plugs
were made with HBL100, HS578T and SUM159PT cell lines. These exhibit a predominantly elongated morphology at day 0. Clear invasion into
surrounding collagen is seen by day 7 (left panels, arrows). Cell-Matrigel plugs with the same lines exhibit a rounded morphology on day 0. By day 7,
HBL100 and HS578T cells have reverted to an elongated morphology and are invading into surrounding collagen. In contrast, SUM159PT cells retain a
rounded morphology accompanied by delayed invasion (day 7) although this appears to be overcome by day 14 (right panels). Dotted lines represent
the original plug edge. Bar = 100 mm.
doi:10.1371/journal.pone.0017083.g004
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This signature in turn was used to identify breast cancer cell lines
that are potentially useful in studying EMT in vitro. A 3D invasion
model was developed that specifically addresses the link between
EMT and invasion into stromal collagen in these cell lines, which
may be representative of a general behaviour. This novel model
was used to examine the expression patterns of cadherins in the
EMT cell lines when invading from the basement membrane
context to a collagen-rich environment.
The association of claudin-low breast cancer and epithelial to
mesenchymal transition is now well established [14,27,36] and cell
lines can be identified with gene expression profiles similar to those
of claudin-low tumors [27]. The low expression signature is also
found in these Basal B/mesenchymal/claudin-low cell lines,
identified elsewhere [27]. Importantly, our results do not single
out a particular EMT inducing transcriptional repressor, although
these are broadly expressed (ZEB2, Snail and Slug) in the cell lines.
This suggests that the induction of EMT may result from a
combination of factors, resulting in repression of common
downstream molecules. From a functional point of view, this is
consistent with loss of cell-cell contact as a prerequisite for the
detachment of invading cells from the tumor mass and their
penetration of surrounding stroma [37].
Previously published invasion models have used either pure
collagen environment [38] or non-physiological methylcellulose
[39]. More physiologically relevant basement membrane-contain-
ing models, such as the chick chorioallantoic membrane [40] or
peritoneal basement membrane [41], are inflexible, difficult to
scale up and often have a very low yield. Our in vitro invasion
model potentially offers a deeper investigation of the nature of
EMT. The combination of basement membrane environment and
surrounding collagen stroma maintains and mimics aspects of
EMT in vivo.
The 3D model demonstrated here exemplifies how using the
same cell line simultaneously in both basement membrane
environment and in tissue-like collagen matrix may enable a
better understating of EMT. Two novel observations were made
using this model: within the basement membrane plug, N-
cadherin expression in cells with EMT signature can phenocopy
E-cadherin expression in normal mammary epithelial cells,
maintaining a tight round morphology; and surprisingly, N-
cadherin is lost as cells with EMT signature invade.
Claudin-low breast cancers are likely to represent the most
acute EMT phenotype in vivo, but other subtypes may also present
some EMT features [15,42]. The current study has extended our
Figure 5. Changes in cells undergoing EMT while invading collagen stroma in vitro. (a) SUM159PT cell-Matrigel plugs were fixed at day 14
to monitor morphological changes during collagen invasion. Images of the whole plugs (46magnification, left panel), core (middle panel) and plug
edge (right panel) are shown (both 406magnification). Note the organised, rounded morphology in Matrigel (middle panel) in contrast to the
elongated morphology as cells invade into surronding collagen (right panel), indicative of EMT. (b) E-cadherin expression in MCF10A cells is
comparable to N-cadherin expression in SUM159PT cells. Representative immunofluorescence images of E-cadherin and N-cadherin protein
expression in MCF10A (left panel) and SUM159PT cells (right panel) are shown. Expression within the plug (core) and at the edge where cells are seen
to invade surrounding collagen (arrows) is compared. Note the change in morphology as cells invade. Bar = 50 mm.
doi:10.1371/journal.pone.0017083.g005
Spontaneous Breast Cancer EMT In Vitro
PLoS ONE | www.plosone.org 7 February 2011 | Volume 6 | Issue 2 | e17083
understanding of common mechanisms of EMT in breast cancer.
This study showed that the down-regulation of cell-cell contact
molecules in claudin-low cancers is accompanied by changes in
HGF signalling and apical sorting molecules. Furthermore, the 3D
model has questioned the concept of a ‘cadherin switch’ in vivo. We
have also observed elsewhere that in invasive ductal breast
carcinomas there is no inverse correlation between E-cadherin and
N-cadherin protein expression levels (S. Dubois-Marshall and E.
Katz, unpublished observations). This raises the possibility that
single cell invasion is cadherin-independent. This will to be
verified in future experiments examining other cadherin molecules
involved in cell motility, such as cadherin-11 [13]. Taken together,
the 3D model presented here gives an opportunity to explore these
possibilities relating to EMT as it may occur in vivo in claudin-low
breast cancers and beyond.
Supporting Information
Figure S1 Comparison of genes correlating with C35
expression and those identifying the claudin-low pheno-
type. Full details of C35 and claudin-low signatures shown in
Fig. 1.
(TIF)
Figure S2 Claudin-low cell lines exhibit a mesenchymal
morphology. Eight claudin-low cell lines were identified.
Representative live microscopy images of these lines cultured on
plastic are shown. The non-transformed cell line, MCF10A, is
shown for comparison. Bar = 100 mm.
(TIF)
Figure S3 Morphology of cell-collagen assays. SUM159PT
cell-collagen plugs were fixed at day 14 following a period of
invasion Images of the whole plugs (46magnification, left panel),
core (middle panel) and plug edge (right panel) are shown (both 406
magnification). Note the consistently elongated cell morphology
unlike cell-Matrigel assays (Figure 5a).
(TIF)
Figure S4 Comparable invasion of SUM159PT cells
regardless of the presence or type of fibroblasts in the
surrounding collagen. Comparable invasion of SUM159PT
cells is seen with no, normal and cancer-associated fibroblasts.
This is seen with both cell-collagen (top panel) and cell-Matrigel
(bottom panel) plugs. H&E staining relating to fixation at day 6 is
shown here. Bar = 100 mm.
(TIF)
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